#POLB Poolbeg Pharma – SIGNIFICANT MILESTONE FOR POOLBEG’S IP PORTFOLIO March 31, 2026 – Posted in: Poolbeg Pharma (POLB)
Grant of first POLB 001 cancer immunotherapy-induced CRS patent Significant milestone for Poolbeg’s global intellectual property portfolio 31 March 2026 – Poolbeg Pharma (AIM: POLB, ‘Poolbeg’ or the ‘Company’), a clinical-stage biopharmaceutical company with a core focus on transforming the cancer immunotherapy field, announces that it has received formal notification of the grant for its POLB 001 cancer immunotherapy-induced Cytokine Release Syndrome (“CRS”) patent application from IP Australia, the Australian patent office. This represents the…
Continue reading